Table 1. Biologics Monoclonal Antibodies Drug Market Size & CAGR: China VS Global, (US$ Million), 2018-2029

Table 2. Biologics Monoclonal Antibodies Drug Market Restraints

Table 3. Biologics Monoclonal Antibodies Drug Market Trends

Table 4. Biologics Monoclonal Antibodies Drug Industry Policy

Table 5. Global Biologics Monoclonal Antibodies Drug Revenue by Company (2018-2023) & (US$ million)

Table 6. Global Biologics Monoclonal Antibodies Drug Revenue Market Share by Company (2018-2023)

Table 7. Global Biologics Monoclonal Antibodies Drug Manufacturers Market Concentration Ratio (CR3 and HHI)

Table 8. Global Biologics Monoclonal Antibodies Drug Mergers & Acquisitions, Expansion Plans

Table 9. Global Biologics Monoclonal Antibodies Drug Manufacturers Product Type

Table 10. China Biologics Monoclonal Antibodies Drug Revenue by Company (2018-2023) & (US$ million)

Table 11. China Biologics Monoclonal Antibodies Drug Revenue Market Share by Company (2018-2023)

Table 12. Global Key Players of Biologics Monoclonal Antibodies Drug Upstream (Raw Materials)

Table 13. Global Biologics Monoclonal Antibodies Drug Typical Customers

Table 14. Biologics Monoclonal Antibodies Drug Typical Distributors

Table 15. By Type, Global Biologics Monoclonal Antibodies Drug Revenue & CAGR, 2018 VS 2022 VS 2029, US$ Million

Table 16. By Application, Global Biologics Monoclonal Antibodies Drug Revenue & CAGR, 2018 VS 2022 VS 2029, US$ Million

Table 17. By Region, Global Biologics Monoclonal Antibodies Drug Market Size, 2018 VS 2022 VS 2029, US$ Million

Table 18. By Region, Global Biologics Monoclonal Antibodies Drug Revenue, 2018-2029, US$ Million

Table 19. By Country, Global Biologics Monoclonal Antibodies Drug Revenue & CAGR，2018 VS 2022 VS 2029, US$ Million

Table 20. By Country, Global Biologics Monoclonal Antibodies Drug Revenue, 2018-2029, US$ Million

Table 21. By Country, Global Biologics Monoclonal Antibodies Drug Revenue Market Share, 2018-2029

Table 22. Roche Company Information, Head Office, Market Area and Industry Position

Table 23. Roche Company Profile and Main Business

Table 24. Roche Biologics Monoclonal Antibodies Drug Models, Specifications and Application

Table 25. Roche Biologics Monoclonal Antibodies Drug Revenue and Gross Margin, 2018-2023

Table 26. Roche Recent Developments

Table 27. Amgen Company Information, Head Office, Market Area and Industry Position

Table 28. Amgen Company Profile and Main Business

Table 29. Amgen Biologics Monoclonal Antibodies Drug Models, Specifications and Application

Table 30. Amgen Biologics Monoclonal Antibodies Drug Revenue and Gross Margin, 2018-2023

Table 31. Amgen Recent Developments

Table 32. AbbVie Company Information, Head Office, Market Area and Industry Position

Table 33. AbbVie Company Profile and Main Business

Table 34. AbbVie Biologics Monoclonal Antibodies Drug Models, Specifications and Application

Table 35. AbbVie Biologics Monoclonal Antibodies Drug Revenue and Gross Margin, 2018-2023

Table 36. AbbVie Recent Developments

Table 37. Sanofi Company Information, Head Office, Market Area and Industry Position

Table 38. Sanofi Company Profile and Main Business

Table 39. Sanofi Biologics Monoclonal Antibodies Drug Models, Specifications and Application

Table 40. Sanofi Biologics Monoclonal Antibodies Drug Revenue and Gross Margin, 2018-2023

Table 41. Sanofi Recent Developments

Table 42. Johnson & Johnson Company Information, Head Office, Market Area and Industry Position

Table 43. Johnson & Johnson Company Profile and Main Business

Table 44. Johnson & Johnson Biologics Monoclonal Antibodies Drug Models, Specifications and Application

Table 45. Johnson & Johnson Biologics Monoclonal Antibodies Drug Revenue and Gross Margin, 2018-2023

Table 46. Johnson & Johnson Recent Developments

Table 47. Pfizer Company Information, Head Office, Market Area and Industry Position

Table 48. Pfizer Company Profile and Main Business

Table 49. Pfizer Biologics Monoclonal Antibodies Drug Models, Specifications and Application

Table 50. Pfizer Biologics Monoclonal Antibodies Drug Revenue and Gross Margin, 2018-2023

Table 51. Pfizer Recent Developments

Table 52. Eli Lilly Company Information, Head Office, Market Area and Industry Position

Table 53. Eli Lilly Company Profile and Main Business

Table 54. Eli Lilly Biologics Monoclonal Antibodies Drug Models, Specifications and Application

Table 55. Eli Lilly Biologics Monoclonal Antibodies Drug Revenue and Gross Margin, 2018-2023

Table 56. Eli Lilly Recent Developments

Table 57. Novartis Company Information, Head Office, Market Area and Industry Position

Table 58. Novartis Company Profile and Main Business

Table 59. Novartis Biologics Monoclonal Antibodies Drug Models, Specifications and Application

Table 60. Novartis Biologics Monoclonal Antibodies Drug Revenue and Gross Margin, 2018-2023

Table 61. Novartis Recent Developments

Table 62. Merck Company Information, Head Office, Market Area and Industry Position

Table 63. Merck Company Profile and Main Business

Table 64. Merck Biologics Monoclonal Antibodies Drug Models, Specifications and Application

Table 65. Merck Biologics Monoclonal Antibodies Drug Revenue and Gross Margin, 2018-2023

Table 66. Merck Recent Developments

Table 67. Biogen Company Information, Head Office, Market Area and Industry Position

Table 68. Biogen Company Profile and Main Business

Table 69. Biogen Biologics Monoclonal Antibodies Drug Models, Specifications and Application

Table 70. Biogen Biologics Monoclonal Antibodies Drug Revenue and Gross Margin, 2018-2023

Table 71. Biogen Recent Developments

Table 72. Sobi Company Information, Head Office, Market Area and Industry Position

Table 73. Sobi Company Profile and Main Business

Table 74. Sobi Biologics Monoclonal Antibodies Drug Models, Specifications and Application

Table 75. Sobi Biologics Monoclonal Antibodies Drug Revenue and Gross Margin, 2018-2023

Table 76. Sobi Recent Developments

Table 77. Innovent Biologics Company Information, Head Office, Market Area and Industry Position

Table 78. Innovent Biologics Company Profile and Main Business

Table 79. Innovent Biologics Biologics Monoclonal Antibodies Drug Models, Specifications and Application

Table 80. Innovent Biologics Biologics Monoclonal Antibodies Drug Revenue and Gross Margin, 2018-2023

Table 81. Innovent Biologics Recent Developments

List of Figure

Figure 1. Biologics Monoclonal Antibodies Drug Picture

Figure 2. Global Biologics Monoclonal Antibodies Drug Industry Market Size and Forecast (US$ million) & (2018-2029)

Figure 3. China Biologics Monoclonal Antibodies Drug Revenue and Forecast (US$ million) & (2018-2029)

Figure 4. 2018-2029 China Biologics Monoclonal Antibodies Drug Market Share of Global

Figure 5. Global Biologics Monoclonal Antibodies Drug Key Participants, Market Share, 2021 VS 2022 VS 2023

Figure 6. Global Biologics Monoclonal Antibodies Drug Market Share by Company, (Tier 1, Tier 2 and Tier 3), 2018-2023

Figure 7. China Biologics Monoclonal Antibodies Drug Key Participants, Market Share, 2021 VS 2022 VS 2023

Figure 8. China Biologics Monoclonal Antibodies Drug Revenue, Domestic VS Import Products, Proportion of China Local Players and Foreign Players, 2018-2023

Figure 9. Biologics Monoclonal Antibodies Drug Industry Chain

Figure 10. Infliximab

Figure 11. Rituximab

Figure 12. Trastuzumab

Figure 13. Adalimumab

Figure 14. Other

Figure 15. By Type, Global Biologics Monoclonal Antibodies Drug Revenue, 2018-2029, US$ Million

Figure 16. By Type, Global Biologics Monoclonal Antibodies Drug Revenue Market Share, 2018-2029

Figure 17. Cancer

Figure 18. Autoimmune Disease

Figure 19. Other

Figure 20. By Application, Global Biologics Monoclonal Antibodies Drug Revenue, 2018-2029, US$ Million

Figure 21. By Application, Global Biologics Monoclonal Antibodies Drug Revenue Market Share, 2018-2029

Figure 22. By Region, Global Biologics Monoclonal Antibodies Drug Revenue Market Share, 2018-2029

Figure 23. North America Biologics Monoclonal Antibodies Drug Revenue & Forecasts, 2018-2029, US$ Million

Figure 24. By Country, North America Biologics Monoclonal Antibodies Drug Revenue Market Share, 2018-2023

Figure 25. Europe Biologics Monoclonal Antibodies Drug Revenue & Forecasts, 2018-2029, US$ Million

Figure 26. By Country, Europe Biologics Monoclonal Antibodies Drug Revenue Market Share, 2018-2023

Figure 27. Asia Pacific Biologics Monoclonal Antibodies Drug Revenue & Forecasts, 2018-2029, US$ Million

Figure 28. By Country/Region, Asia Pacific Biologics Monoclonal Antibodies Drug Revenue Market Share, 2018-2023

Figure 29. South America Biologics Monoclonal Antibodies Drug Revenue & Forecasts, 2018-2029, US$ Million

Figure 30. By Country, South America Biologics Monoclonal Antibodies Drug Revenue Market Share, 2018-2023

Figure 31. Middle East & Africa Biologics Monoclonal Antibodies Drug Revenue & Forecasts, 2018-2029, US$ Million

Figure 32. U.S. Biologics Monoclonal Antibodies Drug Revenue, 2018-2029, (US$ Million)

Figure 33. By Company, U.S. Biologics Monoclonal Antibodies Drug Market Share, 2018-2023

Figure 34. By Type, U.S. Biologics Monoclonal Antibodies Drug Revenue Market Share, 2022 VS 2029

Figure 35. By Application, U.S. Biologics Monoclonal Antibodies Drug Revenue Market Share, 2022 VS 2029

Figure 36. Europe Biologics Monoclonal Antibodies Drug Revenue, 2018-2029, (US$ Million)

Figure 37. By Company, Europe Biologics Monoclonal Antibodies Drug Market Share, 2018-2023

Figure 38. By Type, Europe Biologics Monoclonal Antibodies Drug Revenue Market Share, 2022 VS 2029

Figure 39. By Application, Europe Biologics Monoclonal Antibodies Drug Revenue Market Share, 2022 VS 2029

Figure 40. China Biologics Monoclonal Antibodies Drug Revenue, 2018-2029, (US$ Million)

Figure 41. By Company, China Biologics Monoclonal Antibodies Drug Market Share, 2018-2023

Figure 42. By Type, China Biologics Monoclonal Antibodies Drug Revenue Market Share, 2022 VS 2029

Figure 43. By Application, China Biologics Monoclonal Antibodies Drug Revenue Market Share, 2022 VS 2029

Figure 44. Japan Biologics Monoclonal Antibodies Drug Revenue, 2018-2029, (US$ Million)

Figure 45. By Company, Japan Biologics Monoclonal Antibodies Drug Market Share, 2018-2023

Figure 46. By Type, Japan Biologics Monoclonal Antibodies Drug Revenue Market Share, 2022 VS 2029

Figure 47. By Application, Japan Biologics Monoclonal Antibodies Drug Revenue Market Share, 2022 VS 2029

Figure 48. South Korea Biologics Monoclonal Antibodies Drug Revenue, 2018-2029, (US$ Million)

Figure 49. By Company, South Korea Biologics Monoclonal Antibodies Drug Market Share, 2018-2023

Figure 50. By Type, South Korea Biologics Monoclonal Antibodies Drug Revenue Market Share, 2022 VS 2029

Figure 51. By Application, South Korea Biologics Monoclonal Antibodies Drug Revenue Market Share, 2022 VS 2029

Figure 52. Southeast Asia Biologics Monoclonal Antibodies Drug Revenue, 2018-2029, (US$ Million)

Figure 53. By Company, Southeast Asia Biologics Monoclonal Antibodies Drug Market Share, 2018-2023

Figure 54. By Type, Southeast Asia Biologics Monoclonal Antibodies Drug Revenue Market Share, 2022 VS 2029

Figure 55. By Application, Southeast Asia Biologics Monoclonal Antibodies Drug Revenue Market Share, 2022 VS 2029

Figure 56. India Biologics Monoclonal Antibodies Drug Revenue, 2018-2029, (US$ Million)

Figure 57. By Company, India Biologics Monoclonal Antibodies Drug Market Share, 2018-2023

Figure 58. By Type, India Biologics Monoclonal Antibodies Drug Revenue Market Share, 2022 VS 2029

Figure 59. By Application, India Biologics Monoclonal Antibodies Drug Revenue Market Share, 2022 VS 2029

Figure 60. Middle East & Asia Biologics Monoclonal Antibodies Drug Revenue, 2018-2029, (US$ Million)

Figure 61. By Company, Middle East & Asia Biologics Monoclonal Antibodies Drug Market Share, 2018-2023

Figure 62. By Type, Middle East & Asia Biologics Monoclonal Antibodies Drug Revenue Market Share, 2022 VS 2029

Figure 63. By Application, Middle East & Asia Biologics Monoclonal Antibodies Drug Revenue Market Share, 2022 VS 2029

Figure 64. Research Methodology

Figure 65. Breakdown of Primary Interviews

Figure 66. Bottom-up Approaches

Figure 67. Top-down Approaches